BPC-157 Research in the UK: What the Studies Show and Don't Show
BPC-157 is a 15-amino-acid peptide with a long record in animal and cell studies. Most of that record comes from a small number of research groups, and recent independent reviews describe the evidence in cautious terms. UK readers searching for BPC-157 will find a lot of commentary, so this guide sticks to what BPC-157 is and what those reviews say about the research behind it. For a shorter introduction, see our post What Is BPC-157 Peptide?
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It weighs about 1,420 daltons, and four of its 15 amino acids are proline. For laboratory work it is supplied as BPC-157 10mg or BPC-157 20mg lyophilised. It is based on part of a protein found in human gastric juice, and reviews from the Zagreb group that first described it call it stable in water and gastric juice. Both the origin and the stability come from that group's own publications, so they are best treated as reported claims.
Which Pathways Have Researchers Proposed?
Several, mostly from cell and rodent studies. A 2017 study by Hsieh and colleagues used a chick membrane test, a rat model of restricted blood flow in the hind limb and human blood-vessel cells. BPC-157 increased the VEGFR2 receptor and switched on a VEGFR2-Akt-eNOS signalling pathway, while VEGF-A itself was unchanged.
A 2014 study in rat tendon cells found that BPC-157 turned up the growth hormone receptor, and adding growth hormone then increased cell growth. A review also links tendon cell outgrowth and movement to FAK-paxillin signalling. A 2025 literature and patent review names nitric oxide, especially from the eNOS enzyme, as the main proposed target.
What Do Independent Reviews Say About the Evidence?
A 2025 systematic review in HSS Journal screened 544 articles and included 36, and 35 of those were preclinical. The studies were too different from one another to combine into a meta-analysis, data on how the body processes the peptide came from only three studies, and no animal data on adverse events ran beyond six weeks.
The 2025 review in Pharmaceuticals says most studies are limited to small animal models. It describes one animal study of how the peptide is processed, in rats and dogs, which found a half-life under 30 minutes and six breakdown products. It also notes that no toxic dose has been determined. Other reviews add that many of the studies come from the same group and that the mechanisms are not fully understood.
What Would Make the Evidence Stronger?
Repeating the work in independent laboratories, following animals for longer and defining how the peptide is processed would close the gaps the reviews describe. For work with the peptide itself, the identity and purity of each batch should be recorded, because results from different lots can only be compared when the material is characterised. The reports on our lab reports page are one example of that record.
Important: This article is for scientific information only. The peptides discussed are intended exclusively for scientific and laboratory research and are not intended for human or veterinary consumption, administration, diagnosis, treatment or therapeutic use.